Advertisement
Advertisement
ANVS
Annovis Bio, Inc.
2.00
USDSponsored
+0.03
+1.52%
May 01, 15:59 UTC -4
Closed
After-Market
2.00
0.00
0.00%
ANVS Earnings Reports
Positive Surprise Ratio
ANVS beat 10 of 21 last estimates.
48%
Next Report
Date of Next Report
May 11, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/-$0.39
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Implied change from Q1 25 (Revenue/ EPS)
--
/+21.88%
Annovis Bio, Inc. earnings per share and revenue
On Mar 13, 2026, ANVS reported earnings of -0.39 USD per share (EPS) for Q4 25, missing the estimate of -0.35 USD, resulting in a -11.36% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +12.30% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 5 analysts forecast an EPS of -0.39 USD, with revenue projected to reach -- USD, implying an increase of 0.00% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
NovoCure Limited Ordinary Shares
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.52
Actual
-$0.62
Surprise
-18.52%
Phathom Pharmaceuticals, Inc. Common Stock
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.32
Actual
-$0.18
Surprise
+45.22%
Pacira BioSciences, Inc. Common Stock
Report Date
Apr 30, 2026 For Q1 26
Estimate
$0.57
Actual
$0.60
Surprise
+4.42%
Emergent Biosolutions, Inc.
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.25
Actual
$0.21
Surprise
+183.17%
Amgen Inc
Report Date
Apr 30, 2026 For Q1 26
Estimate
$4.85
Actual
$5.15
Surprise
+6.15%
Bristol-Myers Squibb Co.
Report Date
Apr 30, 2026 For Q1 26
Estimate
$1.42
Actual
$1.58
Surprise
+10.95%
Alnylam Pharmaceuticals, Inc.
Report Date
Apr 30, 2026 For Q1 26
Estimate
$0.95
Actual
$1.99
Surprise
+108.95%
Moderna, Inc. Common Stock
Report Date
May 01, 2026 For Q1 26
Estimate
-$3.32
Actual
-$1.18
Surprise
+64.48%
Illumina Inc
Report Date
Apr 30, 2026 For Q1 26
Estimate
$1.07
Actual
$1.14
Surprise
+6.94%
Bio-Rad Laboratories, Inc. Class B
Report Date
Apr 30, 2026 For Q1 26
Estimate
$2.00
Actual
$1.89
Surprise
-5.68%
FAQ
What were Annovis Bio, Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Annovis Bio, Inc. reported EPS of -$0.39, missing estimates by -11.36%, and revenue of $0.00, 0% as expectations.
How did the market react to Annovis Bio, Inc.'s Q4 2025 earnings?
The stock price moved up 12.3%, changed from $2.52 before the earnings release to $2.83 the day after.
When is Annovis Bio, Inc. expected to report next?
The next earning report is scheduled for May 11, 2026.
What are the forecasts for Annovis Bio, Inc.'s next earnings report?
Based on 5
analysts, Annovis Bio, Inc. is expected to report EPS of -$0.39 and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement